Citi analyst Joanne Wuensch lowered the firm’s price target on Sight Sciences (SGHT) to $3 from $4.60 and keeps a Neutral rating on the shares. The firm adjusted medical technology models post the Q4 reports. The prints “were largely benign compared to a chaotic” Q2 and Q3, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
Questions or Comments about the article? Write to editor@tipranks.com